annual EBITDA:
$178.28M+$88.24M(+98.00%)Summary
- As of today (May 29, 2025), SUPN annual EBITDA is $178.28 million, with the most recent change of +$88.24 million (+98.00%) on December 31, 2024.
- During the last 3 years, SUPN annual EBITDA has risen by +$49.09 million (+38.00%).
- SUPN annual EBITDA is now -15.32% below its all-time high of $210.54 million, reached on December 31, 2020.
Performance
SUPN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$17.79M-$27.44M(-60.67%)Summary
- As of today (May 29, 2025), SUPN quarterly EBITDA is $17.79 million, with the most recent change of -$27.44 million (-60.67%) on March 31, 2025.
- Over the past year, SUPN quarterly EBITDA has increased by +$1.29 million (+7.79%).
- SUPN quarterly EBITDA is now -73.31% below its all-time high of $66.64 million, reached on September 30, 2020.
Performance
SUPN quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$175.08M+$1.29M(+0.74%)Summary
- As of today (May 29, 2025), SUPN TTM EBITDA is $175.08 million, with the most recent change of +$1.29 million (+0.74%) on March 31, 2025.
- Over the past year, SUPN TTM EBITDA has increased by +$99.66 million (+132.14%).
- SUPN TTM EBITDA is now -16.99% below its all-time high of $210.91 million, reached on December 31, 2020.
Performance
SUPN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SUPN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +98.0% | +7.8% | +132.1% |
| 3 y3 years | +38.0% | -53.2% | +21.9% |
| 5 y5 years | +0.8% | -51.3% | -3.6% |
SUPN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +98.0% | -72.7% | +294.6% | at high | +132.1% |
| 5 y | 5-year | -15.3% | +98.0% | -73.3% | +294.6% | -17.0% | +132.1% |
| alltime | all time | -15.3% | +313.1% | -73.3% | +171.0% | -17.0% | +309.2% |
SUPN EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $17.79M(-60.7%) | $175.08M(+0.7%) |
| Dec 2024 | $178.28M(+98.0%) | $45.23M(-30.5%) | $173.79M(+14.9%) |
| Sep 2024 | - | $65.05M(+38.3%) | $151.23M(+28.2%) |
| Jun 2024 | - | $47.02M(+185.0%) | $117.93M(+56.4%) |
| Mar 2024 | - | $16.50M(-27.2%) | $75.42M(-16.2%) |
| Dec 2023 | $90.04M(-41.3%) | $22.67M(-28.6%) | $90.04M(-27.9%) |
| Sep 2023 | - | $31.75M(+604.2%) | $124.96M(+7.5%) |
| Jun 2023 | - | $4.51M(-85.5%) | $116.27M(-20.6%) |
| Mar 2023 | - | $31.12M(-46.0%) | $146.45M(-4.5%) |
| Dec 2022 | $153.36M(+18.7%) | $57.58M(+149.8%) | $153.36M(+31.7%) |
| Sep 2022 | - | $23.05M(-33.5%) | $116.47M(-13.7%) |
| Jun 2022 | - | $34.69M(-8.8%) | $134.97M(-6.0%) |
| Mar 2022 | - | $38.03M(+83.8%) | $143.60M(+11.2%) |
| Dec 2021 | $129.19M(-38.6%) | $20.69M(-50.2%) | $129.19M(-19.3%) |
| Sep 2021 | - | $41.56M(-4.1%) | $160.18M(-13.5%) |
| Jun 2021 | - | $43.32M(+83.4%) | $185.26M(-6.4%) |
| Mar 2021 | - | $23.62M(-54.3%) | $198.01M(-6.1%) |
| Dec 2020 | $210.54M(+19.0%) | $51.68M(-22.5%) | $210.91M(+1.6%) |
| Sep 2020 | - | $66.64M(+18.9%) | $207.55M(+10.5%) |
| Jun 2020 | - | $56.07M(+53.5%) | $187.84M(+3.4%) |
| Mar 2020 | - | $36.52M(-24.4%) | $181.58M(+2.7%) |
| Dec 2019 | $176.85M(+7.0%) | $48.32M(+3.0%) | $176.84M(+1.3%) |
| Sep 2019 | - | $46.93M(-5.8%) | $174.58M(+1.8%) |
| Jun 2019 | - | $49.81M(+56.7%) | $171.48M(+5.3%) |
| Mar 2019 | - | $31.79M(-31.0%) | $162.83M(-1.5%) |
| Dec 2018 | $165.35M(+49.9%) | $46.06M(+5.1%) | $165.35M(+5.9%) |
| Sep 2018 | - | $43.82M(+6.5%) | $156.17M(+11.7%) |
| Jun 2018 | - | $41.16M(+20.0%) | $139.79M(+10.4%) |
| Mar 2018 | - | $34.31M(-7.0%) | $126.61M(+14.8%) |
| Dec 2017 | $110.32M | $36.88M(+34.4%) | $110.32M(+21.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | $27.44M(-1.9%) | $90.61M(+7.7%) |
| Jun 2017 | - | $27.99M(+55.4%) | $84.13M(+22.0%) |
| Mar 2017 | - | $18.01M(+4.9%) | $68.96M(+19.2%) |
| Dec 2016 | $57.86M(+185.0%) | $17.17M(-18.0%) | $57.86M(+17.5%) |
| Sep 2016 | - | $20.95M(+63.4%) | $49.26M(+45.4%) |
| Jun 2016 | - | $12.82M(+85.5%) | $33.87M(+35.3%) |
| Mar 2016 | - | $6.91M(-19.4%) | $25.03M(+23.3%) |
| Dec 2015 | $20.30M(-641.9%) | $8.57M(+53.9%) | $20.30M(+13.4%) |
| Sep 2015 | - | $5.57M(+39.8%) | $17.89M(+51.5%) |
| Jun 2015 | - | $3.98M(+82.9%) | $11.81M(-5.8%) |
| Mar 2015 | - | $2.18M(-64.7%) | $12.54M(-434.9%) |
| Dec 2014 | -$3.75M(-95.5%) | $6.17M(-1297.3%) | -$3.75M(-87.5%) |
| Sep 2014 | - | -$515.00K(-110.9%) | -$29.99M(-40.6%) |
| Jun 2014 | - | $4.71M(-133.4%) | -$50.51M(-37.1%) |
| Mar 2014 | - | -$14.11M(-29.7%) | -$80.27M(-4.1%) |
| Dec 2013 | -$83.68M(+100.0%) | -$20.08M(-4.5%) | -$83.68M(+10.0%) |
| Sep 2013 | - | -$21.03M(-16.1%) | -$76.09M(+12.8%) |
| Jun 2013 | - | -$25.05M(+42.9%) | -$67.45M(+31.6%) |
| Mar 2013 | - | -$17.52M(+40.3%) | -$51.27M(+22.6%) |
| Dec 2012 | -$41.84M(+13.9%) | -$12.49M(+0.8%) | -$41.84M(+6.7%) |
| Sep 2012 | - | -$12.39M(+39.7%) | -$39.22M(+7.4%) |
| Jun 2012 | - | -$8.87M(+9.7%) | -$36.52M(+1.9%) |
| Mar 2012 | - | -$8.09M(-18.0%) | -$35.83M(-2.9%) |
| Dec 2011 | -$36.73M(-4.1%) | -$9.87M(+1.8%) | -$36.88M(-20.0%) |
| Sep 2011 | - | -$9.69M(+18.5%) | -$46.13M(+26.6%) |
| Jun 2011 | - | -$8.18M(-10.6%) | -$36.44M(+28.9%) |
| Mar 2011 | - | -$9.15M(-52.2%) | -$28.26M(+47.8%) |
| Dec 2010 | -$38.29M(-834.9%) | -$19.12M(+42.3%) | -$19.12M(+42.3%) |
| Dec 2009 | $5.21M(-122.0%) | -$13.44M | -$13.44M |
| Dec 2008 | -$23.69M(+45.0%) | - | - |
| Dec 2007 | -$16.34M | - | - |
FAQ
- What is Supernus Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual EBITDA year-on-year change?
- What is Supernus Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Supernus Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals TTM EBITDA year-on-year change?
What is Supernus Pharmaceuticals annual EBITDA?
The current annual EBITDA of SUPN is $178.28M
What is the all time high annual EBITDA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual EBITDA is $210.54M
What is Supernus Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, SUPN annual EBITDA has changed by +$88.24M (+98.00%)
What is Supernus Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of SUPN is $17.79M
What is the all time high quarterly EBITDA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly EBITDA is $66.64M
What is Supernus Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, SUPN quarterly EBITDA has changed by +$1.29M (+7.79%)
What is Supernus Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of SUPN is $175.08M
What is the all time high TTM EBITDA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high TTM EBITDA is $210.91M
What is Supernus Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, SUPN TTM EBITDA has changed by +$99.66M (+132.14%)